+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Immune Checkpoint Inhibitor"

From
From
Immunotherapy Drugs - Global Strategic Business Report - Product Thumbnail Image

Immunotherapy Drugs - Global Strategic Business Report

  • Report
  • May 2025
  • 193 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • May 2025
  • 277 Pages
  • Global
From
Testicular Cancer Market Report 2025 - Product Thumbnail Image

Testicular Cancer Market Report 2025

  • Report
  • April 2025
  • 175 Pages
  • Global
From
Allergy Immunotherapy Market Report 2025 - Product Thumbnail Image

Allergy Immunotherapy Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Cancer Immunotherapy Market Report 2025 - Product Thumbnail Image

Cancer Immunotherapy Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
From
From
From
AXL Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

AXL Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
From
Mesothelioma - Pipeline Insight, 2025 - Product Thumbnail Image

Mesothelioma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025 - Product Thumbnail Image

Anti-CD279 (PD-1) Antibody - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Thumbnail Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
IPSC Derived NK Cells- Pipeline Insight, 2025 - Product Thumbnail Image

IPSC Derived NK Cells- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Advanced Urothelial Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Urothelial Carcinoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Phaeochromocytoma - Pipeline Insight, 2025 - Product Thumbnail Image

Phaeochromocytoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Pheochromocytoma- Pipeline Insight, 2025 - Product Thumbnail Image

Pheochromocytoma- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

Immune Checkpoint Inhibitor drugs are a type of immunotherapy used to treat immune disorders. They work by blocking proteins that act as “checkpoints” in the immune system, allowing the body to recognize and attack cancer cells. These drugs are used to treat a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. They are also used to treat autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. Immune Checkpoint Inhibitor drugs are a relatively new form of treatment, and the market is still in its early stages. However, the potential of these drugs has led to a surge in research and development, with many companies investing in the development of new drugs. Some of the major companies in the Immune Checkpoint Inhibitor market include Bristol-Myers Squibb, Merck, AstraZeneca, Roche, and Novartis. Other companies such as Pfizer, AbbVie, and Johnson & Johnson are also involved in the development of these drugs. Show Less Read more